Literature DB >> 19630809

New insight into the mechanism of action of IVIg: the role of dendritic cells.

A R Crow1, D Brinc, A H Lazarus.   

Abstract

Intravenous immunoglobulin (IVIg) is used to treat an ever-increasing number of autoimmune diseases. While the exact mechanism of action of IVIg has remained elusive, many theories have been suggested, including mononuclear phagocytic system blockade, autoantibody neutralization by anti-idiotype antibodies, accelerated pathogenic autoantibody clearance by saturation of the neonatal Fc receptor, cytokine modulation and complement neutralization. More recently, a key role for dendritic cells (DC) in the amelioration of autoimmunity by IVIg has been suggested. Here we will focus on the role that DC may play in IVIg function using data from both mouse and human studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19630809     DOI: 10.1111/j.1538-7836.2009.03420.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  14 in total

Review 1.  The role of sialic acid as a modulator of the anti-inflammatory activity of IgG.

Authors:  Sybille Böhm; Inessa Schwab; Anja Lux; Falk Nimmerjahn
Journal:  Semin Immunopathol       Date:  2012-03-22       Impact factor: 9.623

Review 2.  Targeting B cells and autoantibodies in the therapy of autoimmune diseases.

Authors:  Daniela Kao; Anja Lux; Inessa Schwab; Falk Nimmerjahn
Journal:  Semin Immunopathol       Date:  2014-04-29       Impact factor: 9.623

Review 3.  Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation.

Authors:  Arno Kornberg
Journal:  World J Hepatol       Date:  2015-06-18

4.  Immunoglobulin: production, mechanisms of action and formulations.

Authors:  Marcia Cristina Zago Novaretti; Carla Luana Dinardo
Journal:  Rev Bras Hematol Hemoter       Date:  2011

Review 5.  Bench-to-bedside review: Immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective.

Authors:  Manu Shankar-Hari; Jo Spencer; William A Sewell; Kathryn M Rowan; Mervyn Singer
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

6.  Successful management of severe refractory acquired immune bleeding disorder: Prior to insisting surgery.

Authors:  Hassan Al-Jafar; H Al-Barjas; Raed A Hashem; Thanaa M K Refaii; Ahmad M AlSaeed
Journal:  Int J Surg Case Rep       Date:  2014-10-31

7.  Dose-dependent inhibition of demyelination and microglia activation by IVIG.

Authors:  Meike Winter; Christine Baksmeier; Julia Steckel; Sumanta Barman; Manish Malviya; Melanie Harrer-Kuster; Hans-Peter Hartung; Norbert Goebels
Journal:  Ann Clin Transl Neurol       Date:  2016-09-23       Impact factor: 4.511

8.  Amelioration of murine passive immune thrombocytopenia by IVIg and a therapeutic monoclonal CD44 antibody does not require the Myd88 signaling pathway.

Authors:  Andrew R Crow; Honghui Yu; Dongji Han; Alan H Lazarus
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

Review 9.  Regulatory dendritic cells for immunotherapy in immunologic diseases.

Authors:  John R Gordon; Yanna Ma; Laura Churchman; Sara A Gordon; Wojciech Dawicki
Journal:  Front Immunol       Date:  2014-01-31       Impact factor: 7.561

10.  Circulating Th17, Th22, and Th1 cells are elevated in the Guillain-Barré syndrome and downregulated by IVIg treatments.

Authors:  Shujuan Li; Tao Jin; Hong-Liang Zhang; Hong Yu; Fanhua Meng; Hernan Concha Quezada; Jie Zhu
Journal:  Mediators Inflamm       Date:  2014-05-12       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.